As filed with the Securities and Exchange Commission on March 31, 2006.

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

 

March 31, 2006 (March 31, 2006)

 

 

MEDAREX, INC.

(Exact name of registrant as specified in its charter)

 

 

707 State Road, Princeton, N.J. 08540-1437

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (609) 430-2880

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

o            Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

MEDAREX, INC.

TABLE OF CONTENTS

FOR

CURRENT REPORT ON FORM 8-K

 

Item 8.01	Other Events
Item 9.01	Financial Statements and Exhibits
Signature

 

2

 

Item 8.01.                                         Other Events.

 

On March 31, 2006, Medarex, Inc. issued a press release announcing the initiation of a registrational clinical trial studying ipilimumab (also known as MDX-010) as a monotherapy in previously-treated metastatic melanoma patients. Medarex is developing ipilimumab in collaboration with Bristol-Myers Squibb Company.

 

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01                                                                                            Financial Statements and Exhibits.

 

(d)                                 Exhibits.

 

Exhibit
Number
99.1		Medarex, Inc. Press Release dated March 31, 2006.

 

3

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	MEDAREX, INC.
	Registrant
Date: March 31, 2006	By:	/s/ Christian S. Schade
	Christian S. Schade
	Senior Vice President and Chief
	Financial Officer

 

4

 

EXHIBIT INDEX

 

Exhibit Number		Description		Page Number
99.1		Medarex, Inc. Press Release dated March 31, 2006.

 

5